Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00415-013-6901-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Considering ivermectin for treatment of schistosomiasis.
Parasitol Res
April 2024
Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Because of recent reports of praziquantel resistance in schistosome infections, there have been suggestions to employ ivermectin as a possible alternative, especially as its chemical composition is different from that of praziquantel, so cross-resistance is not expected. In order to ascertain possible damage and elimination of worms, we used ivermectin by oral gavage in infected mice, at a high dose (30.1 mg/kg, bordering toxicity).
View Article and Find Full Text PDFPediatric Spinal Neuroschistosomiasis in Yemen: An Overlooked Dilemma in an Endemic Region.
Cureus
July 2023
Department of Internal Medicine, Hadhramaut University, Hadhramaut, YEM.
Background: Neurological involvement in schistosomiasis presents a significant and serious complication. While the disease is generally considered treatable during the early stages, the rarity of this condition often leads to delays in diagnosis and treatment. This study aims to report the clinical characteristics of pediatric patients with spinal neuroschistosomiasis (NS) in an endemic area to the disease.
View Article and Find Full Text PDFGenetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel.
Sci Transl Med
December 2021
Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Article Synopsis
- - Mass drug administration with praziquantel (PZQ) is the primary method used to control schistosomiasis, but many parasites show reduced sensitivity to the drug, leading researchers to study the genetic factors behind this resistance in a specific PZQ-selected population.
- - The study identified a gene related to a transient receptor potential (TRPM) channel that influences how schistosomiasis parasites respond to PZQ, revealing a significant difference in PZQ resistance levels between resistant and sensitive parasite populations.
- - By analyzing genetic variations in the TRPM channel across different global parasite samples, researchers discovered a mutation that prevents PZQ from binding, highlighting the need for monitoring these resistant strains in efforts to eliminate schistos
Case Report: Diagnosis and Assessment of Cure Approaches for Acute Schistosomiasis in Pre-School Children.
Front Immunol
September 2021
Departmento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Acute schistosomiasis (AS) manifests with a broad spectrum of clinical features in pediatric populations. Diagnosis may be difficult in the absence of detectable numbers of eggs. As a result, new approaches may be required to achieve an accurate diagnosis.
View Article and Find Full Text PDFNanostructured lipid carriers for enhanced and schistosomicidal activity of praziquantel: effect of charge.
Drug Dev Ind Pharm
April 2021
Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta, Tanta, Egypt.
WHO considers praziquantel (PZQ) as the drug of choice for treatment of infection but this requires high dose due to poor solubility and first pass metabolism. The aim of this work was to optimize nanostructured lipid carriers (NLCs) for enhanced PZQ oral delivery. The optimization involved testing the effect of surface charge of NLCs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!